KRMD Rasio cepet KORU Medical Systems, Inc.

KORU Medical Systems (KRMD) develops high-tech home medication infusion systems, focusing on digital solutions and micropumps. However, regulatory delays and competitor pressure in the home treatment segment create certain risks. This price action reflects the 2.15 metric. Revenue growth from Freedom system sales via the ARR model provides the company with a steady cash flow, offsetting current operating expenses.

Investors must weigh liquid assets against short-term liabilities to assess resilience to cash flow gaps. This metric aggregates cash and accounts receivable, completely excluding slow-moving inventory. For infusion systems manufacturer KORU Medical Systems (KRMD), this is critical, as a massive volume of plastic components does not constitute a liquid asset. Analyzing the current state of quick liquidity allows for the timely detection of excessive capital freezing.